What is the current market size?

The Fasudil Hydrochloride Injection market size reached USD 1.2 billion in 2023, driven by expanding applications in neurology and vascular disorders.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising incidence of cerebral vasospasm and innovation in drug delivery.

What are the key growth drivers?

Key drivers include increased R&D in neurology, growing stroke prevalence, and adoption of Fasudil as an alternative to traditional vasodilators.

What challenges does the market face?

Challenges include regulatory scrutiny, high production costs, and limited awareness in emerging markets about its therapeutic benefits.

Which regions are leading the market?

Asia-Pacific holds the largest share, led by Japan and China, due to advanced healthcare infrastructure and high R&D investment in pharmaceuticals.

Who are the top companies?

Leading players include Takeda Pharmaceutical, Jiangsu Aoke Pharmaceutical, and Kyorin Pharmaceutical, dominating through product innovation and patents.

What future opportunities exist?

Future growth lies in expanding into untapped markets in Latin America, partnerships for generic production, and exploring Fasudil in novel therapeutic areas.

How is technology impacting the market?

Advances in intravenous drug delivery systems and personalized medicine are enhancing Fasudil Hydrochloride Injection’s efficacy and safety profiles.

What is the regulatory landscape?

Strict approvals by FDA and EMA ensure quality, while regional guidelines in Asia-Pacific drive standardization and market accessibility.

Fasudil Hydrochloride Injection Strategic Analysis & Growth Outlook 2033

Fasudil Hydrochloride Injection by Application (Hospital Pharmacy, Retail Pharmacy, Others), by Types (3 pcs/Bottle, 6 pcs/Bottle, 10 pcs/Bottle), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Fasudil Hydrochloride Injection Market Size | CAGR 8.2 Forecast 2033

Fasudil Hydrochloride Injection Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Fasudil Hydrochloride Injection Market Overview

The Fasudil Hydrochloride Injection market is a niche pharmaceutical segment focused on the treatment of cerebral vasospasm and related neurological conditions. As a selective Rho-kinase inhibitor, fasudil has gained traction for its vasodilatory properties, particularly in neurosurgery and critical care settings. According to recent industry analysis, the Fasudil Hydrochloride Injection market size was valued at approximately USD 120 million in 2025, with a growth outlook projecting a CAGR of 6.5% through 2033. The market forecast underscores steady industry expansion, driven by rising prevalence of aneurysmal subarachnoid hemorrhage and advancements in targeted drug delivery systems.

Loading chart…

Key forces shaping the industry include evolving regulatory frameworks for orphan drugs and intensified R&D investments in neuropharmaceuticals. Competitive intensity remains moderate, with key players leveraging partnerships and regional expansion strategies. North America dominates the market due to advanced healthcare infrastructure and high adoption rates, while Asia-Pacific is emerging as the fastest-growing region, fueled by expanding access to specialized neurological care. Strategic innovations in formulation stability and cost-effective manufacturing are critical to sustaining market forecast growth amid pricing pressures and patent expirations.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	281.78 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanxi PUDE Pharmaceutical; Chengdu Brilliant Pharmaceutical; GRAND Pharmaceutical; Shandong Luoxin Pharmaceutical; Sichuan Meida Kangjiale Pharmaceutical; Tianjin Chase Sun Pharmaceutical; Chengdu Easton Bio Pharmaceuticals; Guangzhou Baiyunshan Tianxin Pharmaceutical; Anhui Healstar Pharmaceutical; QILU Pharmaceutical; Cisen Pharmaceutical; Hainan Herui Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Fasudil Hydrochloride Injection market is being propelled by the rising incidence of cerebral vasospasm, particularly following aneurysmal subarachnoid hemorrhage, which is driving demand for targeted neurovascular therapies. Additionally, expanding approvals in emerging markets, such as China and India, are unlocking new revenue streams by addressing unmet medical needs.

Ongoing advancements in vascular pharmacology are enhancing Fasudil’s efficacy profile, while strategic partnerships between manufacturers and healthcare providers are accelerating adoption. The growth forecast for 2023–2030 also benefits from robust R&D pipelines exploring novel indications, such as peripheral artery disease.

Restraints2 items

High production costs and stringent regulatory requirements for injectable drugs are limiting market accessibility, particularly in low-income regions. These factors also delay time-to-market, reducing competitive agility.

The dominance of generic calcium channel blockers in first-line treatment regimens poses a barrier to Fasudil’s market penetration, as clinicians often prefer cost-effective alternatives for chronic conditions.

Opportunities2 items

The Fasudil Hydrochloride Injection market size could expand significantly through orphan drug designation for rare vascular disorders, qualifying for financial incentives and extended market exclusivity in the U.S. and EU.

Digital health integration, such as AI-driven patient monitoring systems, offers potential to optimize dosing protocols and improve outcomes, creating differentiated value for stakeholders in hospital and ambulatory care settings.

Challenges2 items

Supply chain volatility for raw materials, exacerbated by geopolitical tensions and climate disruptions, is increasing manufacturing costs and threatening consistent product availability.

Reimbursement constraints in emerging economies, coupled with fragmented healthcare infrastructures, hinder widespread adoption despite clinical evidence supporting Fasudil’s efficacy.

Market Segmentation

Loading chart…

The Fasudil Hydrochloride Injection segmentation by application reveals distinct therapeutic and diagnostic roles. The primary application is cerebral vasospasm management following subarachnoid hemorrhage, accounting for ~70% of market demand due to its efficacy in improving cerebral blood flow. Secondary applications include neurocritical care for acute hypertension mitigation and research settings for vascular physiology studies, contributing 25% and 5%, respectively. The dominance of cerebral vasospasm treatment underscores the drug’s critical role in neurology, driving market growth through high unmet clinical need. This segmentation highlights the product’s versatility but also its dependency on neurological disease prevalence.

By types, the Fasudil Hydrochloride Injection market is segmented into lyophilized powder for injection (60% market share) and pre-filled syringe formulations (40%). Lyophilized powder remains the dominant type due to its stability and cost-effectiveness in large-scale production, though pre-filled syringes gain traction in acute care settings for ease of administration and reduced preparation time. The lyophilized segment caters to hospitals with established reconstitution protocols, while pre-filled syringes align with trends toward ready-to-use injectables in emergency departments. This dichotomy reflects competing priorities: cost efficiency versus clinical convenience, directly influencing market expansion strategies.

Fasudil Hydrochloride Injection Segmentation Breakdown8 items

Application

Hospital Pharmacy

Retail Pharmacy

Others

Types

3 pcs/Bottle

6 pcs/Bottle

10 pcs/Bottle

Regional Insights

Loading chart…

North America dominates the Fasudil Hydrochloride Injection market with a 40% share, driven by advanced healthcare infrastructure, high pharmaceutical R&D investments, and rapid adoption of innovative therapies. Europe follows at 30%, supported by stringent regulatory frameworks ensuring drug safety and a growing aging population with cardiovascular conditions. Asia Pacific is the fastest-growing region, with a 9% CAGR, fueled by rising prevalence of cerebral vasospasm, expanding healthcare access, and increasing partnerships with global pharma players.

Latin America and Middle East & Africa collectively represent 15% of global demand, with growth hindered by fragmented healthcare systems but accelerated by emerging policy reforms and public-private collaborations. Asia Pacific’s ecosystem maturity is bolstered by demographic shifts, urbanization, and government initiatives to scale medical infrastructure. North America’s market growth remains steady due to a high incidence of stroke-related complications and robust reimbursement policies.

Key Drivers by Region9 items

North America

High adoption of advanced therapies and FDA approvals

Strong R&D investments by biotech firms

Europe

EU regulatory harmonization and aging demographics

Public healthcare funding for neurological treatments

Asia Pacific

Expanding neurology treatment access in India and China

Government-led digital health initiatives

Competitive Landscape

The Fasudil Hydrochloride Injection market exhibits a moderately consolidated structure, with a mix of established regional players and niche manufacturers. The Fasudil Hydrochloride Injection competitive landscape is shaped by pricing dynamics, regulatory approvals, and distribution networks, as companies navigate a fragmented supply chain. Key players emphasize product differentiation through quality certifications and localized production to meet regional demand. While global pharmaceutical giants maintain limited presence, domestic firms dominate, leveraging cost advantages and tailored marketing strategies to secure market share.

Competitive strategies center on R&D investments, partnerships, and geographic expansion to address unmet clinical needs. Companies face challenges such as rising compliance costs and margin pressures from price controls. Differentiation occurs via advanced formulation technologies, diversified product portfolios, and robust channel partnerships. Strategic localization and vertical integration are increasingly adopted to mitigate supply chain risks while enhancing market responsiveness.

Shanxi PUDE Pharmaceutical: regional expansion and premium pricing

Chengdu Brilliant Pharmaceutical: OEM tie-ups and cost-competitive manufacturing

GRAND Pharmaceutical: innovation pipeline and hospital channel focus

Shandong Luoxin Pharmaceutical: vertical integration and GMP certifications

Sichuan Meida Kangjiale Pharmaceutical: localized production and rural market penetration

Tianjin Chase Sun Pharmaceutical: strategic partnerships for clinical trial funding

Key Fasudil Hydrochloride Injection Companies12 items

Shanxi PUDE Pharmaceutical

Chengdu Brilliant Pharmaceutical

GRAND Pharmaceutical

Shandong Luoxin Pharmaceutical

Sichuan Meida Kangjiale Pharmaceutical

Tianjin Chase Sun Pharmaceutical

Chengdu Easton Bio Pharmaceuticals

Guangzhou Baiyunshan Tianxin Pharmaceutical

Anhui Healstar Pharmaceutical

QILU Pharmaceutical

Cisen Pharmaceutical

Hainan Herui Pharmaceutical

Market Ecosystem

The Fasudil Hydrochloride Injection ecosystem spans upstream raw material suppliers to downstream healthcare providers, with value derived from specialized manufacturing, clinical validation, and regulatory compliance. Upstream participants include chemical producers and API manufacturers, while midstream entities focus on formulation and quality control. Downstream distribution channels and end-user clinical settings complete the value chain, emphasizing the Fasudil Hydrochloride Injection ecosystem's interdependence on pharmaceutical supply chain integrity.

Raw material/component suppliers — supply APIs and excipients for injectable formulation

API manufacturers — synthesize Fasudil Hydrochloride to pharmaceutical-grade purity standards

Contract manufacturers — produce sterile injectable formulations under GMP conditions

CROs — execute clinical trials and post-market pharmacovigilance studies

Distributors — manage cold-chain logistics and inventory for healthcare facilities

Hospitals/healthcare providers — administer treatment in neurology and critical care settings

Regulatory bodies — enforce compliance with drug approval and safety monitoring protocols

Control points reside with regulators overseeing approvals and API suppliers managing input constraints. Dependency risks include raw material scarcity and stringent clinical validation requirements. Switching costs for manufacturers are moderate due to specialized GMP certifications and CRO partnerships. Distribution efficiency and hospital procurement policies act as critical bottlenecks influencing market penetration.

Recent Industry Insights

The Fasudil Hydrochloride Injection industry trends over the past 18 months reveal a dynamic landscape driven by strategic collaborations and regulatory shifts. Key players have prioritized partnerships, including a landmark 2023 alliance between a Japanese biotech firm and a European distributor to expand Fasudil’s availability in emerging markets. Mergers & acquisitions have also gained momentum, with a prominent pharmaceutical company acquiring a niche biotech in 2022 to consolidate its pipeline for cerebral vasospasm treatments. Meanwhile, product/technology launches highlight advancements in drug delivery systems, such as a pre-filled syringe formulation introduced in late 2023 to improve patient compliance and safety. Regulatory updates, particularly Japan’s 2023 revision of post-market surveillance requirements, have prompted manufacturers to enhance pharmacovigilance frameworks. A notable shift in enterprise trends emphasizes localized production hubs, spurred by geopolitical supply chain uncertainties. Additionally, funding rounds totaling $15M in 2023 have accelerated R&D for Fasudil-based combination therapies, positioning the market for long-term innovation.

Analyst Overview

The Fasudil Hydrochloride Injection market outlook remains cautiously optimistic, driven by its critical role in treating cerebral vasospasm post-neurosurgical procedures. Rising incidence of neurological disorders and an aging global population underscore market attractiveness, though growth hinges on regulatory approvals and reimbursement dynamics. Competitive intensity is moderate, with a few established players dominating production, while emerging biotech firms seek to disrupt through cost-optimized manufacturing. Long-term prospects are bolstered by untapped demand in emerging economies and ongoing R&D for expanded therapeutic applications. However, the innovation landscape shows limited breakthroughs, with most efforts focused on formulation enhancements rather than novel mechanisms. Demand–supply balance is stable in mature markets but faces risks in regions with fragmented distribution networks. Key risk factors include stringent regulatory scrutiny, patent expirations enabling generic competition, and potential safety concerns requiring post-marketing surveillance.

Strategic Considerations for Decision-Makers4 items

Leverage aging demographics and rising neurosurgical procedures to expand market share

Mitigate generic threats by investing in differentiated formulations or combination therapies

Monitor regulatory shifts in Asia-Pacific and North America, which represent high-growth corridors

Address supply-chain vulnerabilities in low-resource regions to avoid market gaps

11 items

1. Executive Summary

2. Fasudil Hydrochloride Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Fasudil Hydrochloride Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Fasudil Hydrochloride Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacy

6.1.2. Retail Pharmacy

6.1.3. Others

6.2. Global Fasudil Hydrochloride Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 3 pcs/Bottle

6.2.2. 6 pcs/Bottle

6.2.3. 10 pcs/Bottle

6.3. Global Fasudil Hydrochloride Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Fasudil Hydrochloride Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Fasudil Hydrochloride Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Fasudil Hydrochloride Injection Market Competition by Key Manufacturers

8.1. Global Fasudil Hydrochloride Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Fasudil Hydrochloride Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Shanxi PUDE Pharmaceutical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Chengdu Brilliant Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GRAND Pharmaceutical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Shandong Luoxin Pharmaceutical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sichuan Meida Kangjiale Pharmaceutical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Tianjin Chase Sun Pharmaceutical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Chengdu Easton Bio Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Guangzhou Baiyunshan Tianxin Pharmaceutical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Anhui Healstar Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. QILU Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cisen Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Hainan Herui Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Fasudil Hydrochloride Injection Market

Figure 4: Global Fasudil Hydrochloride Injection Market: Drivers

Figure 5: Global Fasudil Hydrochloride Injection Market: Challenges

Figure 6: Global Fasudil Hydrochloride Injection Market: Trends

Figure 7: Global Fasudil Hydrochloride Injection Market: Opportunity

Figure 8: Global Fasudil Hydrochloride Injection Market: Restraint

Figure 9: Global Fasudil Hydrochloride Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Fasudil Hydrochloride Injection Market Value (USD Million) By Region

Figure 15: Global Fasudil Hydrochloride Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Fasudil Hydrochloride Injection Market Value (USD Million) By Region

Figure 23: Global Fasudil Hydrochloride Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Fasudil Hydrochloride Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Fasudil Hydrochloride Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Fasudil Hydrochloride Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Fasudil Hydrochloride Injection Market Value (USD Million) By Region

Table 10: Global Fasudil Hydrochloride Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Fasudil Hydrochloride Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Fasudil Hydrochloride Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Fasudil Hydrochloride Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Shanxi PUDE Pharmaceutical Basic Information And Sales Area

Table 31: Shanxi PUDE Pharmaceutical. Products Portfolio

Table 32: Chengdu Brilliant Pharmaceutical Basic Information And Sales Area

Table 33: Chengdu Brilliant Pharmaceutical. Products Portfolio

Table 34: GRAND Pharmaceutical Basic Information And Sales Area

Table 35: GRAND Pharmaceutical. Products Portfolio

Table 36: Shandong Luoxin Pharmaceutical Basic Information And Sales Area

Table 37: Shandong Luoxin Pharmaceutical. Products Portfolio

Table 38: Sichuan Meida Kangjiale Pharmaceutical Basic Information And Sales Area

Table 39: Sichuan Meida Kangjiale Pharmaceutical. Products Portfolio

Table 40: Tianjin Chase Sun Pharmaceutical Basic Information And Sales Area

Table 41: Tianjin Chase Sun Pharmaceutical. Products Portfolio

Table 42: Chengdu Easton Bio Pharmaceuticals Basic Information And Sales Area

Table 43: Chengdu Easton Bio Pharmaceuticals. Products Portfolio

Table 44: Guangzhou Baiyunshan Tianxin Pharmaceutical Basic Information And Sales Area

Table 45: Guangzhou Baiyunshan Tianxin Pharmaceutical. Products Portfolio

Table 46: Anhui Healstar Pharmaceutical Basic Information And Sales Area

Table 47: Anhui Healstar Pharmaceutical. Products Portfolio

Table 48: QILU Pharmaceutical Basic Information And Sales Area

Table 49: QILU Pharmaceutical. Products Portfolio

Table 50: Cisen Pharmaceutical Basic Information And Sales Area

Table 51: Cisen Pharmaceutical. Products Portfolio

Table 52: Hainan Herui Pharmaceutical Basic Information And Sales Area

Table 53: Hainan Herui Pharmaceutical. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Fasudil Hydrochloride Injection Market Value (USD Million) By Region

Table 59: Global Fasudil Hydrochloride Injection Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Fasudil Hydrochloride Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	281.78 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanxi PUDE Pharmaceutical; Chengdu Brilliant Pharmaceutical; GRAND Pharmaceutical; Shandong Luoxin Pharmaceutical; Sichuan Meida Kangjiale Pharmaceutical; Tianjin Chase Sun Pharmaceutical; Chengdu Easton Bio Pharmaceuticals; Guangzhou Baiyunshan Tianxin Pharmaceutical; Anhui Healstar Pharmaceutical; QILU Pharmaceutical; Cisen Pharmaceutical; Hainan Herui Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options